US-based medical technology company Life Spine has received the US Food & Drug Administration (FDA) approval to market its ARx SAI (Sacral Alar Iliac) Spinal Fixation System.
The ARx SAI Spinal Fixation System is a next-generation posterior fixation technology with versatile implants and streamlined ergonomic instrumentation.
Life Spine said the system can be used through a Sacral Alar Iliac trajectory in S1 or S2, for maximum fixation across the Sacroiliac Joint.
The system facilitates the construction of customised solutions, personalised to each patient’s specific pathology while maintaining ease of use.
Life Spine designed its screw shank based on its successful SImpact SI self-harvesting screw design, which is self-drilling and recruits autograft during insertion.
Life Spine sales and marketing senior vice president Mariusz Knap said: “ARx SAI advances our commitment to innovation, positioning us among the pioneering spine companies to offer an SAI screw within our Lumbar Spinal Fixation Systems portfolio.
“ARx SAI delivers customisable solutions tailored to each patient, ensuring ease of use and versatile trajectory options.”
Life Spine is a medical device company focused on designing, developing, manufacturing, and marketing products for the surgical treatment of spinal disorders.
Its ARx SAI spinal fixation system comes with key features, including self-drilling screws, self-harvesting design, Cobalt Chrome tulip head, and T25 hexalobe drive.
The self-drilling screws help eliminate surgical steps, increase efficiency, and save time, while its self-harvesting design packs bone into fenestrations during insertion.
Also, its low-profile Cobalt Chrome tulip head provides enhanced strength and supports patients of all sizes, while the universal T25 hexalobe drive ensures ease of use, said the company.
